Under the arrangement, prices for GLP-1 drugs—used both for diabetes and obesity—will be slashed for Medicare and Medicaid ...

Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes ...

Popular GLP-1 drugs like Ozempic will get cheaper in exchange for partial Medicare coverage, opening up new markets for Eli ...

Even after Trump’s new deal, obesity drugs are still too expensive.

President Trump's plan drops the price of Ozempic and Wegovy for Americans, with plans for Medicare to cover the popular ...

Now the entire country knows (or at least believes) that Steven Cheung, 43, a longtime comms staffer and attackdog for Trump ...

The deal is with drugmakers Eli Lilly and Novo Nordisk to cut prices of their weight-loss drugs and expand Medicare coverage ...

The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) ...

America's obesity epidemic costs an estimated $173 billion each year. The benefits of covering GLP-1s vastly outweigh the ...

Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with ...

Denmark-based Novo Nordisk, which makes Ozempic, Rybelsus and Wegovy; and Indianapolis-based Eli Lilly, which makes Zepbound, ...